Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use

The FDA has expanded the approval of Vaxneuvance (pneumococcal 15-valent conjugate vaccine) to include 6 weeks through 17 years of age.

Related Keywords

Eliav Barr ,Merck Vaxneuvance ,Merck Research Laboratories ,Drug Administration ,Biologics License Application ,Merck Research ,Accessed June ,